Results 61 to 70 of about 3,199 (152)

Patient‐reported Disease Activity in an Axial Spondyloarthritis Cohort during the COVID‐19 Pandemic

ACR Open Rheumatology, 2020
Objective Response to the coronavirus disease 2019 (COVID‐19) pandemic has resulted in shelter‐in‐place orders and major changes to individuals’ daily lives.
Jean W. Liew, Maria Castillo, Ethan Zaccagnino, Patricia Katz, Nigil Haroon, Lianne S. Gensler   +5 more
doaj   +1 more source

Dual Targeted Therapy as a Treatment Strategy for Refractory Psoriatic Arthritis: Real‐World Effectiveness and Safety From a Prospective Cohort

ACR Open Rheumatology, Volume 8, Issue 8, August 2026.
Objective To describe patient profiles, treatment patterns, clinical outcomes, and safety of intentional dual biologic or targeted synthetic disease‐modifying antirheumatic drug (b/tsDMARD) therapy in psoriatic arthritis (PsA). A subset of patients with PsA continue to experience persistent inflammation despite b/tsDMARD monotherapy.
André Lucas Ribeiro, Zahra Al‐Zahir, Virginia Carrizo Abarza, Khalad Maliyar, Siddhartha Sood, Ahmed Bagit, Muskaan Sachdeva, Sahil Koppikar, Dafna D. Gladman, Jensen Yeung, Vinod Chandran, Lihi Eder   +11 more
wiley   +1 more source

Understanding the drivers of BASDAI and back pain scores in psoriatic arthritis

Annals of the Rheumatic Diseases
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is widely used to assess axial disease activity in psoriatic arthritis (PsA). However, 5 of its 6 questions reflect general disease activity rather than axial-specific symptoms. We aimed to evaluate the performance of BASDAI and its back pain subscore in assessing axial disease in PsA ...
Pankti Mehta, Fadi Kharouf, Virginia Carrizo Abarza, Shangyi Gao, Dafna D Gladman, Vinod Chandran, Denis Poddubnyy   +6 more
openaire   +2 more sources

BASDAI ou ASDAS (en fonction de la CRP, quel score choisir pour évaluer la réponse aux anti-TNF alpha dans les spondyloarthrites axiales?) [PDF]

, 2012
Comparer la proportion de répondeurs aux anti-TNF a déterminés par le BASDAI et l'ASDAS en fonction du syndrome inflammatoire biologique dans une population de patients traités par infliximab pour une spondyloarthrite axiale.
BREHIER, Quentin, LEQUERRE, Thierry
core   +2 more sources

Sex Differences in Medication Discontinuation in Axial Spondyloarthritis

Arthritis Care &Research, Volume 78, Issue 7, Page 914-924, July 2026.
Objective We examined sex differences in medication discontinuation among patients with axial spondyloarthritis (axSpA) initiating tumor necrosis factor inhibitors (TNFi), interleukin‐17 inhibitors (IL‐17i), or JAK inhibitors (JAKi). Methods Using data from the Rheumatology Informatics System for Effectiveness (RISE) Registry (2003–2025), we assessed ...
Rachael Stovall, Cinthia Blat, Eric Roberts, Jean W. Liew, Katherine Wysham, Namrata Singh, Janna Friedly, Lianne S. Gensler, Gabriela Schmajuk, Jinoos Yazdany   +9 more
wiley   +1 more source

Disease Remission: A Scoping Review With Thematic Analysis of the Scientific Literature With Implications for Chronic Rhinosinusitis

International Forum of Allergy &Rhinology, Volume 16, Issue 6, Page 615-629, June 2026.
ABSTRACT Background Remission, a term used to describe a goal of treatment for some chronic diseases, has recently been proposed for chronic rhinosinusitis (CRS). However, it is unclear what remission means for CRS and why it should serve as a goal in the present‐day treatment of CRS.
Nikhil Parail, Lynn Warner, Stacey T. Gray, Claire Hopkins, Peter H. Hwang, Sarah K. Wise, Katie M. Phillips, Ahmad R. Sedaghat   +7 more
wiley   +1 more source

AB0865 Do asas, asdas and basdai therapy response evaluation translate the same information? [PDF]

Annals of the Rheumatic Diseases, 2018
Background The ASAS-EULAR recommendations for the continuation of biological Disease-Modifying Anti-rheumatic Drugs (DMARD) suggest the evaluation of patients after at least 12 weeks of treatment by either the Ankylosing Spondylitis (AS) Disease Activity Score – C reactive protein (ASDAS-CRP) or by the Bath AS Disease Activity Index (BASDAI).
M. Eusébio, J.L. Gomes, M. Bernardes, P. Pinto, H. Santos, J. Tavares-Costa, J. Dias, S. Pimenta, L. Domingues, C. Crespo, S. Maia, F. Martins, J.C. Branco, F.M. Pimentel-Santos   +13 more
openaire   +1 more source

Bilateral Avascular Necrosis of the Femoral Heads in Ankylosing Spondylitis Requiring Staged Total Hip Arthroplasty: A Case Report of Diagnostic and Therapeutic Challenges

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Ankylosing spondylitis (AS) is a chronic immune‐mediated inflammatory arthropathy primarily affecting the axial skeleton but may involve peripheral joints, particularly the hips. Avascular necrosis (AVN) of the femoral head represents a severe, underrecognized complication whose pathogenesis in AS is multifactorial—encompassing disease ...
Syeda Simrah Shah, Muhammad Ahsan, Tehreem Farooq, Mirza Daniyal Baig, Mirza Mohammad Ali Baig, Mohammed Hammad Jaber Amin   +5 more
wiley   +1 more source

Serum chitotriosidase and neopterin levels in patients with ankylosing spondylitis

Therapeutic Advances in Musculoskeletal Disease, 2019
Background: The aim of this study was to assess the serum chitotriosidase (ChT) and neopterin levels in patients with ankylosing spondylitis (AS) and to evaluate whether serum ChT and neopterin levels are related to disease activity.
Ferdi Yavuz, Bilge Kesikburun, Özlem Öztürk, Ümüt Güzelküçük   +3 more
doaj   +1 more source

Validity of Simplified Ankylosing Spondylitis Disease Activity Scores (SASDAS) in Indian Ankylosing Spondylitis Patients [PDF]

Journal of Clinical and Diagnostic Research, 2017
Introduction: Ankylosing Spondylitis Disease Activity Score (ASDAS) is a complex score for monitoring disease activity in Ankylosing Spondylitis (AS). Aim: To develop a simplified version of the ASDAS.
NAGMA BANSAL, LALIT DUGGAL, NEERAJ JAIN
doaj   +1 more source